Skip to main content
    I

    Immunitybio Inc (IBRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.98
    -0.04 (-0.66%)

    Market Cap: $6.40B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Immunitybio Inc (IBRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Immunitybio reported revenue of $113.29M for the fiscal year ended Dec 31, 2025, up 668.3% from the year before. That year, net income was -$351.47M with a net margin of -310.2%, operating cash flow was -$304.94M and free cash flow was -$309.19M. The quarter ended Sep 30, 2026 had revenue of $48.84M and net income of -$184.56M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $44.00K, a compound annual rate of 139.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$113.29M+668.3%99.3%-226.0%-310.2%
    Dec 2024$14.74M+2270.6%100.0%-2334.2%-2805.3%
    Dec 2023$622.00K+159.2%100.0%-58239.5%-93866.9%
    Dec 2022$240.00K-74.3%100.0%-146374.2%-173883.3%
    Dec 2021$934.00K+54.4%100.0%-35361.9%-37457.0%
    Dec 2020$605.00K-72.5%100.0%-36509.1%-37055.7%
    Dec 2019$2.20M+4585.1%100.0%-7095.9%-7273.3%
    Dec 2018$47.00K+4.4%100.0%-209338.3%-204736.2%
    Dec 2017$45.00K+2.3%100.0%-220266.7%-214273.3%
    Dec 2016$44.00KN/A100.0%-282954.5%-274565.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$113.29M$14.74M$622.00K$240.00K$934.00K$605.00K$2.20M$47.00K$45.00K$44.00K
    Cost of revenue$753.00K$0$0$0$0$0$0$0$0$0
    Gross profit$112.53M$14.74M$622.00K$240.00K$934.00K$605.00K$2.20M$47.00K$45.00K$44.00K
    Research and development$218.56M$190.14M$232.37M$248.15M$195.96M$139.51M$112.00M$55.72M$42.04M$29.15M
    Operating income-$256.03M-$344.18M-$362.25M-$351.30M-$330.28M-$220.88M-$156.25M-$98.39M-$99.12M-$124.50M
    Net income-$351.47M-$413.64M-$583.85M-$417.32M-$349.85M-$224.19M-$160.16M-$96.23M-$96.42M-$120.81M
    EBITDA-$232.71M-$228.64MN/A-$302.71M-$315.38M-$205.86M-$142.74M-$88.14M-$91.80M-$118.62M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$48.84M$51.24M$44.21M$64.71M$32.06M$26.43M$16.52M$8.60M$6.11M$0$40.00K$139.00K
    Gross profit$47.55M$50.94M$43.97M$64.64M$31.88M$26.29M$16.46M$8.60M$6.11M$0$40.00K$139.00K
    Operating income-$77.99M-$61.70M-$69.79M$62.23M-$55.63M-$71.28M-$64.43M$110.19M-$160.51M-$198.67M-$95.20M-$85.39M
    Net income-$184.56M-$230.39M-$632.80M$97.89M-$67.27M-$92.57M-$129.67M$161.16M-$171.50M-$269.17M-$134.13M-$233.41M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $810.99M exceeded cash and equivalents by $722.66M. Shareholder equity was negative, at -$500.47M, as total liabilities of $1.00B exceeded total assets of $501.90M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$501.90M$382.93M$504.45M$362.36M$468.91M$221.38M$143.12M$181.95M$250.44M$317.50M
    Current assets$314.88M$184.59M$294.08M$140.58M$334.35M$111.71M$55.76M$88.77M$132.46M$205.15M
    Cash and equivalents$88.33M$143.43M$265.45M$104.64M$181.10M$34.91M$15.51M$16.82M$23.87M$8.08M
    Total liabilities$1.00B$871.06M$1.09B$812.18M$712.82M$339.87M$22.44M$35.94M$31.60M$24.08M
    Short-term debt$9.29M$7.47M$5.24M$431.90M$299.24M$5.01M$3.96M$965.00K$166.00K$187.00K
    Long-term debt$801.71M$746.28M$836.95M$241.27M$306.35M$254.35MN/AN/AN/AN/A
    Shareholder equity-$500.47M-$489.10M-$586.99M-$447.33M-$242.17M-$119.81M$120.68M$146.01M$218.84M$293.42M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$609.39M$628.50M$646.64M$501.90M$518.99M$402.08M$303.76M$382.93M$364.57M$444.32M$400.68M$504.45M
    Total liabilities$1.75B$1.67B$1.52B$1.00B$1.04B$971.89M$894.24M$871.06M$1.11B$1.14B$1.09B$1.09B
    Cash and equivalents$45.08M$75.67M$205.19M$88.33M$60.24M$137.66M$60.66M$143.43M$111.97M$130.10M$133.03M$265.45M
    Shareholder equity-$1.15B-$1.05B-$870.01M-$499.57M-$524.32M-$570.75M-$591.43M-$489.10M-$745.15M-$698.39M-$692.01M-$586.99M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$304.94M-$391.24M-$366.76M-$337.51M-$274.42M-$171.72M-$152.11M-$63.38M-$48.78M-$38.59M
    Capital expenditures$4.25M$6.89M$30.58M$78.16M$33.56M$1.67M$4.29M$13.10M$34.81M$6.56M
    Free cash flow-$309.19M-$398.12M-$397.34M-$415.67M-$307.98M-$173.39M-$156.40M-$76.48M-$83.59M-$45.15M
    Dividends paidN/AN/AN/A$616.00K$334.44M$4.44M$2.28MN/AN/AN/A
    Share repurchasesN/AN/AN/AN/AN/AN/A$2.50M$228.00K$15.23M$15.85M
    Investing cash flow-$149.80M-$12.25M-$30.47M$27.30M-$84.89M-$19.81M$18.55M$57.10M$99.55M-$113.67M
    Financing cash flow$400.24M$281.63M$558.34M$233.61M$505.44M$150.68M$114.28M-$771.00K-$34.98M-$15.56M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$75.33M-$66.49M-$75.36M-$70.38M-$68.91M-$79.75M-$85.91M-$85.14M-$98.76M-$100.35M-$106.98M-$115.27M
    Capital expenditures$2.93M$3.54M$1.79M$1.31M$775.00K$1.08M$1.12M$2.11M$2.79M$724.00K$1.26M$7.96M
    Free cash flow-$78.26M-$70.03M-$77.15M-$71.69M-$69.68M-$80.83M-$87.03M-$87.25M-$101.56M-$101.07M-$108.24M-$123.23M
    Last 12 quarters

    Frequently Asked Questions About IBRX

    What is Immunitybio's annual revenue?

    Immunitybio reported revenue of $113.29M for the fiscal year ended Dec 31, 2025.

    How fast is Immunitybio's revenue growing?

    Revenue was up 668.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 678.6%.

    Is Immunitybio profitable?

    No. Immunitybio reported net income of -$351.47M for the fiscal year ended Dec 31, 2025, with a net margin of -310.2%.

    How much free cash flow does IBRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$304.94M minus capital expenditures of $4.25M produced free cash flow of -$309.19M.

    How much debt does Immunitybio have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $801.71M, short-term debt of $9.29M and cash and equivalents of $88.33M.